Metadherin (MTDH) mRNA (MTDH mRNA)

Metadherin (MTDH) mRNA, also known as Astrocyte elevated gene-1 (AEG-1) mRNA, encodes a multifunctional protein that serves as a central hub in oncogenic signaling and tumor progression [1][2]. The MTDH protein is overexpressed in nearly all human cancers and plays a pivotal role in promoting cell survival, migration, invasion, and resistance to chemotherapy by modulating pathways such as PI3K/Akt, NF-κB, and Wnt/β-catenin [3][4]. Because the MTDH protein lacks a traditional enzymatic pocket, the mRNA transcript has emerged as a primary therapeutic target for RNA-based interventions, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) [5]. These strategies aim to degrade the mRNA or inhibit its translation, thereby reducing the levels of the MTDH protein and disrupting its interaction with partners like Staphylococcal nuclease domain-containing protein 1 (SND1) [6]. Clinical interest in targeting MTDH mRNA is driven by its ability to reverse chemoresistance and inhibit metastasis in aggressive cancer models [7]. Furthermore, MTDH mRNA levels often correlate with poor clinical outcomes, making it both a therapeutic target and a potential prognostic biomarker [8].

Other names

Astrocyte elevated gene-1 (AEG-1) mRNALYRIC mRNA3D3 mRNAMetastasis adhesion protein mRNA

RNA interference-mediated degradation and antisense-mediated translational inhibition